Trial Profile
A Single and Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics SCH 900931 in Healthy Adult Japanese Subjects.
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Verubecestat (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Merck & Co; Schering-Plough
- 22 Jun 2011 New trial record